StreetAlpha.app
Home › Stocks › OTLK

Outlook Therapeutics, Inc. (OTLK)

Healthcare
$0.39
▼ −2.74%
LAST CLOSE · NOV 20

Outlook Therapeutics develops ONS-5010/LYTENAVA, an eye treatment based on bevacizumab for wet macular degeneration. It last closed at $0.39 on Nov 20, down 2.74% on the day. The next earnings report for OTLK is expected around Fri, Dec 18, 2026. For the quarter ended Jun 2026, OTLK reported EPS of -$0.15. Over its last 8 reports the stock moved an average of 8.2% the session after earnings. Over the last 12 months OTLK insiders bought $7.9M of stock on the open market and sold $0, according to SEC Form 4 filings.

AI Auto Pilots
Is OTLK in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold OTLK.

Key Stats

Last 12 months
Results
Net income
−$61.1M
EPS (diluted)
−$0.70
Valuation
Market cap
$94.9M
243.4M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$11.2M
At Jun 30
Shareholder equity
−$10.4M
Shares outstanding
243.4M
At Aug 14
Fiscal year endsSeptember
ExchangeNasdaq
Financials history
FY2021: −$53.2M−$53.2MFY2021FY2022: −$66.1M−$66.1MFY2022FY2023: −$59.0M−$59.0MFY2023FY2024: −$75.4M−$75.4MFY2024FY2025: −$62.4M−$62.4MFY2025

From OTLK's SEC filings, latest 10-Q for the period ending Jun 30, 2026 (filed Aug 18). Last 12 months adds up the four latest quarters.

Next report
Dec 18
Estimated date · Time not announced
Reported EPS
-$0.15
Quarter ended Jun 2026
Year ago EPS
-$0.55
Same quarter last year
Revenue
—
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Sep 2024: $0.76Sep '24Dec 2024: $0.72Dec '24Mar 2025: -$1.50Mar '25Jun 2025: -$0.55Jun '25Sep 2025: -$0.19Sep '25Dec 2025: -$0.38Dec '25Mar 2026: -$0.05Mar '26Jun 2026: -$0.15Jun '26Latest -$0.15
Revenue by quarter
Not enough quarters on file yet.
How OTLK moved after its last 8 reports
Average move the session after a report ±8.2%
Aug 12, 2026After the close−19.2%
May 13, 2026After the close+1.4%
Feb 17, 2026Time not announced−13.8%
Dec 19, 2025Time not announced−2.9%
Aug 14, 2025After the close−3.7%
May 15, 2025After the close+4.5%
Feb 14, 2025Time not announced+1.6%
Dec 27, 2024Time not announced+18.2%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on OTLKStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
Analyst calls from around the web
Last 90 days on OTLK: 0 upgrades, 0 downgrades, 1 initiation
Piper SandlerInitiated
Nov 22  

StreetAlpha's curated list of analyst calls collected from around the web. It may be incomplete or inaccurate, is not a consensus and is not advice.

AI Starter and AI Pro
Full analyst coverage on OTLK
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on OTLK

Technical Analysis

OTLK · as of the Nov 20 close · updated each morning
Downtrend, nearing oversold

The stock is 16% below its 20 day and 38% below its 50 day average. It is 69% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 36), near oversold. The nearest support is the Pivot at $0.38, and the nearest resistance the Pivot R1 at $0.41.

Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityNormal, 11.5%/day
Key levels
$2.5452 week high+551.3%
$0.78100 day average+100.0%
$0.66200 day average+69.2%
$0.5450 day average+38.5%
$0.50Swing high (Nov 11)+28.2%
$0.4520 day average+15.4%
$0.41Pivot R1+5.1%
$0.39Last close
$0.38Pivot−2.6%
$0.37Pivot S1−5.1%
$0.35Swing low (Nov 17)−10.3%
$0.1652 week low−59.0%
Indicators
RSI (14)36.03Weak, oversold below 30Neutral
MACD-0.04Below its signal lineBearish
Stochastic33.5Middle of its rangeNeutral
ADX (14)25.5Trending down
Williams %R-73.0Oversold below −80, overbought above −20Neutral
CCI (20)-125.1Oversold below −100, overbought above 100Oversold
Rate of change−10.6%Change over 10 sessionsBearish
ATR (14)$0.04Typical daily range, 11.5% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for OTLK

What happened before

See how OTLK did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow OTLK usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How OTLK has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2016.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for OTLKHow many large options trades hit OTLK, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

OTLK Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲49 buying vs 23 selling
  • ▲Held by funds +17.7 pts
  • ▲Funds holding +12
  • ▲Superinvestors: 2 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding8270+17.1%
In funds' top 1010–
Held by funds26.1%8.4%+17.7 pts
New / increased26 / 2327 / 20+4.3%
Reduced / sold out10 / 137 / 13+15.0%
Put/call ratio0.000.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See OTLK institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

OTLK Insider Trading

All filings →
Insider trading · 12 months
Insiders are net buyers
Bought$7.9M8 buys · 5 insiders
Sold$00 sales · 0 insiders
Cluster buy: 2 insiders bought $2.6M between Jul 29 and Aug 12.
2026-05 bought $5.2M2026-06 bought $24K2026-07 bought $100K2026-08 bought $2.5MDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Aug 12Ghiath M. SukhtianDirectorBuy2,525,252$0.99$2.5M
Jul 29Faisal Ghiath SukhtianDirectorBuy95,398$1.05$100K
Jun 2Yezan Munther HaddadinDirectorBuy29,000$0.83$24K
May 28Ghiath M. SukhtianDirectorBuy8,539,709$0.59$5.0M
May 27Faisal Ghiath SukhtianDirectorBuy122,174$0.41$50K
May 26Kurt J HilzingerDirectorBuy400,000$0.44$177K
Every insider buy and sale for OTLK over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See OTLK insider trades →

From SEC Form 4 filings by OTLK's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether OTLK is in one of them and how their past OTLK trades turned out.

OTLK in the AI portfolios
Loading…

OTLK News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered OTLK in an article yet. Here's the latest on the wider market.

OTLK in the news

About Outlook Therapeutics

Outlook Therapeutics is a biopharmaceutical company based in Iselin, New Jersey. Its main product is ONS-5010/LYTENAVA, an eye treatment based on bevacizumab, an antibody first approved for cancer and adapted for use in the eye. It is used to treat wet macular degeneration, a condition that can damage central vision. The product is approved in the European Union and the United Kingdom, where the company sells it directly, and it is under review in the United States.

Headquarters
Iselin, NJ